Quarterly ResultApr 23, 2026, 07:16 AM
West Q1 Net Sales Up 21% to $844.9M; Raises FY26 Guidance
AI Summary
West Pharmaceutical Services reported a strong first quarter for 2026, with net sales increasing 21.0% to $844.9 million and adjusted-diluted EPS rising 46.9% to $2.13. This performance was driven by robust organic growth of 15.3%, particularly in High Value Products Components and Delivery Devices, including GLP-1 and non-GLP-1 revenues. As a result of these strong results and anticipated continued momentum, the company has raised its full-year 2026 net sales and adjusted-diluted EPS guidance.
Key Highlights
- Q1 2026 net sales increased 21.0% to $844.9 million; organic growth was 15.3%.
- Q1 2026 diluted EPS rose 56.1% to $1.92; adjusted-diluted EPS increased 46.9% to $2.13.
- Full-year 2026 net sales guidance raised to $3.295B-$3.350B from $3.215B-$3.275B.
- Full-year 2026 adjusted-diluted EPS guidance increased to $8.40-$8.75 from $7.85-$8.20.
- Repurchased 1.2 million shares for $297.6 million at an average price of $243.57.